Using virtual reality to improve the quality of life for cancer patients
Impact of Virtual Reality on the Quality of Life of Oncology Patients
This study is testing if using virtual reality can help cancer patients feel less anxious and sick during their first round of chemotherapy compared to standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital Saint Quentin Government |
| Drugs / interventions | Chemotherapy |
| Locations | 2 sites (Chauny and 1 other locations) |
| Trial ID | NCT06485869 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of immersive virtual reality (VR) in managing anxiety, nausea, and vomiting in cancer patients undergoing their first line of chemotherapy. It employs a controlled, randomized approach with two groups: one receiving VR support during treatment and the other receiving standard care. The study aims to measure improvements in quality of life, patient and nursing staff satisfaction, and the overall impact of VR on symptoms associated with chemotherapy. Participants will be assessed during their chemotherapy sessions and followed up for several months post-treatment.
Who should consider this trial
Good fit: Ideal candidates are chemotherapy-naive patients receiving their first line of intravenous cyclic chemotherapy who can understand French or English.
Not a fit: Patients with severe claustrophobia, psychiatric disorders, or significant communication barriers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life for cancer patients by reducing distressing symptoms during chemotherapy.
How similar studies have performed: Previous studies have shown that virtual reality can effectively alleviate anxiety and distress in similar patient populations, suggesting a promising avenue for treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chemotherapy-naive patient * Patient with first-line indication for intravenous cyclic chemotherapy * Affiliated to a social security system * Having received full information on the organization of the research and having given free, informed and written consent signed by the participant and the investigator * Patient understands French or English * Expected duration of chemotherapy session for the first 3 cycles greater than 30 minutes exclusion criteria : * Patient with communication disorders preventing informed consent * Patient under legal protection (guardianship, curatorship, safeguard of justice) * Patients suffering from epilepsy * Severe visual or hearing impairment preventing use of headphones * Psychiatric pathologies such as delusional disorders, hallucinations or schizophrenia. * Patients with infections or facial wounds * Patients with severe claustrophobia * Patients with pacemakers * Patients with known cognitive or learning problems, * Patients with brain tumors or metastases, * Patients suffering from motion sickness * Expected duration of chemotherapy session for the first 3 cycles of 30 minutes or less.
Where this trial is running
Chauny and 1 other locations
- Centre Hospitalier de Chauny — Chauny, France (Recruiting)
- Centre Hospitalier de Saint Quentin — Saint-Quentin, France (Recruiting)
Study contacts
- Principal investigator: Frédérique Mm Roussel — Ch Saint-Quentin
- Study coordinator: Frédérique Mm Roussel
- Email: f.roussel@ch-stquentin.fr
- Phone: 0323067901
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.